Fractures in postmenopausal women with osteoporosis are prevented by an annual infusion of zoledronic acid;Fractuurpreventie bij postmenopauzale vrouwen met osteoporose door een jaarlijks infuus met zoledroninezuur

Nederlands Tijdschrift voor Geneeskunde

Volumn 151, Issue 26, 2007, Pages 1445-1448

  Geusens, P P M M ^a   Lems, W F ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM; COLECALCIFEROL; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; STRONTIUM; ZOLEDRONIC ACID;

AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; EYE DISEASE; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HUMAN; HYPOCALCEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; OSTEOPOROSIS; POSTMENOPAUSE; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; FRACTURES, BONE; HIP FRACTURES; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; OSTEOPOROSIS, POSTMENOPAUSAL; SPINAL FRACTURES; TREATMENT OUTCOME;

EID: 34447252558     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. HORIZON Pivotal Fracture Trial. N Engl J Med. 2007;356: 1809-22.
2. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535-41.
3. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-82.
4. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000;85:4118-24.
5. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001; 344:333-40.
6. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11:83-91.
7. Watts NB, Josse RG, Hamdy RC, Hughes RA, Manhart MD, Barton I, et al. Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab. 2003;88:542-9.
8. Chesnut CH, Ettinger MP, Miller PD, Baylink DJ, Emkey R, Harris ST, et al. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin. 2005;21:391-401.
9. Delmas PD, Recker RR, Chesnut 3rd CH, Skag A, Stakkestad JA, Emkey R, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int. 2004;15:792-8.
10. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637-45.
11. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004; 350:459-68.
12. Reginster JY, Seeman E, de Vernejoul MC, Adami S, Compston J, Phenekos C, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis. Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005;90:2816-22.
13. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-41.
14. Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Treatment of Osteoporosis with Parathyroid Hormone Study Group. Ann Intern Med. 2007;146:326-39.
15. Russell RG. Determinants of structure-function relationships among bisphosphonates. Bone. 2007;40(5 Suppl 2):S21-5.
16. Compston JE, Seeman E. Compliance with osteoporosis therapy is the weakest link. Lancet. 2006;368:973-4.
17. Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int. 2007;18:271-7.
18. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346:653-61.
19. Kavanagh KL, Guo K, Dunford JE, Wu X, Knapp S, Ebetino FH, et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci USA. 2006;103:7829-34.
20. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753-61.
21. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med. 2007;356:1895-6.
22. Stakkestad JA, Benevolenskaya LI, Stepan JJ, Skag A, Nordby A, Oefjord E, et al. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. Ibandronate Intravenous Study Group. Ann Rheum Dis. 2003;62:969-75.
23. Compston J. Treatments for osteoporosis - looking beyond the HORIZON. N Engl J Med. 2007;356:1878-80.